Document is current
Any future updates will be listed below
-
Authors
Liu, Xi
Estaras, Matías
Cosialls, Emma https://orcid.org/0009-0008-8409-8485
Peng, Ling
Santofimia-Castaño, Patricia https://orcid.org/0000-0003-2506-5567
Iovanna, Juan https://orcid.org/0000-0003-1822-2237
-
Funding
Funding for this research was provided by:
Canceropôle PACA
China Scholarship Council
La ligue contre le cancer, INCa,
- License Information
-
More Information
Article History
Received: 12 March 2025
Revised: 22 September 2025
Accepted: 13 October 2025
First Online: 17 November 2025
Competing interests
: A patent has been filed containing part of this study: PCT filing number n° PCT/EP2025/053879, NUPR1 inhibitors for treating cancer. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
: All methods were performed in accordance with the relevant guidelines and regulations. Ethical approval was obtained from the Animal Experimentation Ethics Committee No. 014, under the authorization number APAFIS#40941-2023021415217230 v4.
: During the preparation of this work, the author(s) used ChatGPT in order to correct the grammar of the text. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.
